72253-28-2

Usage

Uses

Used in Pharmaceutical Industry:
(2-OXOPIPERIDIN-1-YL)ACETIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs targeting a range of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, (2-OXOPIPERIDIN-1-YL)ACETIC ACID is utilized as an intermediate in the production of agrochemicals, potentially contributing to the creation of new compounds for agricultural applications.
Used in Therapeutic Applications:
(2-OXOPIPERIDIN-1-YL)ACETIC ACID is studied for its potential therapeutic use in treating neurological disorders and cardiovascular diseases, highlighting its versatility in medical research and development.

Upstream product

• 151-50-8 potassium cyanide 
• 132353-41-4 2-(4'-Bromobutyl)-5-ethoxyoxazole 
• 216252-69-6 1-t-Butoxycarbonylmethyl-2-piperidone 
• 675-20-7 piperidin-2-one 
• 105-36-2 ethyl bromoacetate 
• 5414-21-1 5-bromopentan-1-nitrile 
• 1309788-57-5 benzyl (2-oxopiperidin-1-yl)acetate 

Downstream Products

• 216252-56-1 RWJ 38063 

Relevant academic research and scientific papers

INTRAMOLECULAR FORMATION OF OXAZOLIUM SALTS AND THEIR REACTION WITH N- AND C-NUCLEOPHILES

We report the first intramolecular formation of an oxazolium salt and its reaction with N- and C-nucleophiles, leading to isolation of piperidine derivatives via azomethine ylides.Trapping of the latter produced tetrahydroindolizines.

INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF

Provided is an agent for the treatment or prophylaxis of inflammatory diseases, allergic diseases, autoimmune diseases, transplant rejection or the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as described in the specification.

NK1 and NK3 antagonists

The invention is to a compound exhibiting neurokinin inhibitory properties, a pharmaceutical composition comprising same and a method of treatment for neurokinin-mediated conditions.

1,3-Dipolar cycloadditions of new mesoionic compounds. Synthesis of 1H-pyrrolo[1,2-c]thiazoles, pyrrolizines and 5,6,7,8-tetrahydroindolizines

We studied the 1,3-dipolar cycloaddition reactions between alkyne dipolarophiles and the new mesoionic compounds 2H,5H,7H-thiazolo[4,3-b]oxazol-2-one (12), 2H,5H,7H-pyrrolo[2,1-b]oxazol-2-one (13) and 2H,5H,7H-oxazolo[3,2-a]pyridin-2-one (14). These 1,3-dipoles were prepared in situ by means of cyclodehydration with acetic anhydride of the corresponding α-substituted 4-oxo-3-thiazolidine- (9), 2-oxo-1-pyrrolidine- (10) and 2-oxo-1-piperidineacetic acids (11). The cycloaddition reactions with alkyne dipolarophiles afforded single 1H-pyrrolo[1,2-c]thiazole, pyrrolizine and 5,6,7,8-tetrahydroindolizine derivatives, or a mixture of the two possible regioisomers, depending on whether symmetrical or unsymmetrical alkynes.

Novel arylpiperazines as selective α1-adrenergic receptor antagonists

A novel series of arylpiperazines has been synthesized and identified as antagonists of α(1a) adrenergic receptor (α(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound α(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known α1-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.

Multipath Reactions between Intramolecularly Formed Oxazolium Salts and Nucleophiles

Reaction of 2-(4'-bromobutyl-5-ethoxyoxazole (1) with nucleophiles led either to SN2 substitution products or to products with a piperidine skeleton.The latter were shown to arise from an intramolecular ring closure to an oxazolium salt 7, whic